Literature DB >> 25341574

Gynecologic Cancer InterGroup (GCIG) consensus review for mucinous ovarian carcinoma.

Jonathan A Ledermann1, Daniela Luvero, Aaron Shafer, Dennis O'Connor, Giorgia Mangili, Michael Friedlander, Jacobus Pfisterer, Mansoor R Mirza, Jae-Weon Kim, Jerome Alexandre, Amit Oza, Jubilee Brown.   

Abstract

Mucinous carcinomas of the ovary can be primary or metastatic in origin. Improvements in the pathological diagnosis have increased the ability to distinguish between primary and metastatic ovarian cancers and shown that primary mucinous carcinomas are a rare subtype of ovarian cancer. Most tumors are diagnosed at an early stage, and the prognosis after surgery is good. Advanced or recurrent mucinous carcinoma of the ovary responds poorly to current cytotoxic treatments, and the prognosis is poor. Here, we review the guidelines for surgery and the results of treatment of advanced and recurrent disease. Chemotherapy with platinum and paclitaxel is currently used to treat advanced disease, but the effect of these drugs is modest, and new treatments are needed.

Entities:  

Mesh:

Year:  2014        PMID: 25341574     DOI: 10.1097/IGC.0000000000000296

Source DB:  PubMed          Journal:  Int J Gynecol Cancer        ISSN: 1048-891X            Impact factor:   3.437


  21 in total

1.  Mutant p53 Promotes Epithelial Ovarian Cancer by Regulating Tumor Differentiation, Metastasis, and Responsiveness to Steroid Hormones.

Authors:  Yi A Ren; Lisa K Mullany; Zhilin Liu; Alan J Herron; Kwong-Kwok Wong; JoAnne S Richards
Journal:  Cancer Res       Date:  2016-03-10       Impact factor: 12.701

2.  Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup (GCIG): clinical trial design for rare ovarian tumours.

Authors:  A F Leary; M Quinn; K Fujiwara; R L Coleman; E Kohn; T Sugiyama; R Glasspool; I Ray-Coquard; N Colombo; M Bacon; A Zeimet; A Westermann; E Gomez-Garcia; D Provencher; S Welch; W Small; D Millan; A Okamoto; G Stuart; K Ochiai
Journal:  Ann Oncol       Date:  2017-04-01       Impact factor: 32.976

3.  Effectiveness of postoperative chemotherapy for stage IC mucinous ovarian cancer.

Authors:  Koji Matsuo; Yongmei Huang; Oliver Zivanovic; Muneaki Shimada; Hiroko Machida; Brendan H Grubbs; Lynda D Roman; Jason D Wright
Journal:  Gynecol Oncol       Date:  2019-07-04       Impact factor: 5.482

Review 4.  Options for the Treatment of Mucinous Ovarian Carcinoma.

Authors:  Olivia Craig; Carolina Salazar; Kylie L Gorringe
Journal:  Curr Treat Options Oncol       Date:  2021-11-13

5.  A Rare Presentation of Dual Ovarian Pathologies: Small Cell Carcinoma of the Ovary and Mucinous Ovarian Cancer.

Authors:  Syed A Mannan; Musa Azhar; Jhanzeb Iftikhar; Saad Khalil Chaudhry; Maryam Hameed
Journal:  Cureus       Date:  2021-11-11

6.  The Chicago Consensus on Peritoneal Surface Malignancies: Management of Ovarian Neoplasms.

Authors: 
Journal:  Ann Surg Oncol       Date:  2020-04-13       Impact factor: 5.344

Review 7.  Advanced Ovarian Cancer: Primary or Interval Debulking? Five Categories of Patients in View of the Results of Randomized Trials and Tumor Biology: Primary Debulking Surgery and Interval Debulking Surgery for Advanced Ovarian Cancer.

Authors:  Amin P Makar; Claes G Tropé; Philippe Tummers; Hannelore Denys; Katrien Vandecasteele
Journal:  Oncologist       Date:  2016-03-23

8.  Evolving population-based statistics for rare epithelial ovarian cancers.

Authors:  Koji Matsuo; Hiroko Machida; Shinya Matsuzaki; Brendan H Grubbs; Maximilian Klar; Lynda D Roman; Anil K Sood; David M Gershenson; Jason D Wright
Journal:  Gynecol Oncol       Date:  2020-01-15       Impact factor: 5.482

Review 9.  Molecular Signatures of Gynecological Cancers: Clinicians Perspective.

Authors:  T S Shylasree; Bansal Richa; Gurram Lavanya; Seema Gulia
Journal:  Indian J Surg Oncol       Date:  2021-02-02

10.  Does size matter? Retrospective analysis of large gynecologic tumors.

Authors:  Tufan Öge; Emel Öztürk; Ömer T Yalçın
Journal:  J Turk Ger Gynecol Assoc       Date:  2017-12-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.